With the recent FDA approval of neoadjuvant chemotherapy and nivolumab for Stage IB-IIIA NSCLC, does the fact that the study used AJCC 7th edition staging impact your patient selection at all since we currently are using 8th edition staging?   


Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice